C

Commodore Capital, LP

13 employees

Commodore Capital is invested in the early stages of a major innovation cycle in biopharmaceuticals.

Investor insights

Sectors invested in

Biotechnology9
Health Care6
Medical4
Therapeutics4
Pharmaceutical3
Life Science3
Biopharma2
Biopharmaceuticals1
Pharmaceuticals1
Therapeutics for the treatment of rare diseases1
Innovation Management1
Speciality Biopharmaceuticals1
Oncology1
gastrointestinal stromal tumors (GIST)1
Systemic Mastocytosis1
kinase inhibitors1
Autoimmune disease1

Funding rounds participated in

$100M sweet spot round size

Most of their 11 investments are in rounds between $70M and $105M

Investor type

Venture Capital

Basic info

Industry

investment management
financial services

Sectors

Date founded

2019

Investments made

S

Soleno Therapeutics, Inc. raised $129M on September 28, 2023

Investors: Perceptive Advisors, Woodline Partners LP, Adage Capital Management and Commodore Capital, LP

I

Immunic Therapeutics raised $60M on October 10, 2022

Investors: Great Point Partners, Logos Global Management, LP, RTW Investments, LP, The Invus Group, Parkman Healthcare Partners LLC, Vivo Capital and Commodore Capital, LP

I

Immunovant raised $75M on October 4, 2022

Investors: TCG X, Logos Global Management, LP and Commodore Capital, LP

A

Allakos Inc raised $150M on September 19, 2022

Investors: TCG X, Vivo Capital, Surveyor Capital, RTW Investments, LP, Logos Global Management, LP and Commodore Capital, LP

U

Undisclosed raised $100M on May 16, 2022

Investors: Soleus Capital Management, L.P., RA Capital Management, L.P. and Commodore Capital, LP

T

Third Harmonic Bio raised $105M on January 16, 2022

Investors: RA Capital Management, L.P., RTW Investments, LP, Ajax Health, General Atlantic and Commodore Capital, LP

U

Undisclosed raised $105M on July 13, 2021

Investors: Atlas Venture, Surveyor Capital, Logos Global Management, LP, RA Capital Management, L.P. and Commodore Capital, LP

-

- raised $80M on March 1, 2021

Investors: Point72 Asset Management, Vivo Capital, RA Capital Management, L.P., Surveyor Capital, Logos Global Management, LP, SNBL USA, Aspire Capital Partners, LLC and Commodore Capital, LP

S

Shoreline Biosciences, Inc. raised $43M on February 7, 2021

Investors: -, Stork Capital S.à.r.l., Gilead Capital LP, Logos Global Management, LP, Cormorant Capital and Commodore Capital, LP

C

Cogent Biosciences raised $104M on July 6, 2020

Investors: Logos Global Management, LP, Atlas Venture, Perceptive Advisors, RTW Investments, LP, OrbiMed Advisors, Samsara BioCapital and Commodore Capital, LP

FAQ